作者
Mochamad Yusuf Alsagaff, Eka Prasetya Budi Mulia, Irma Maghfirah, Kevin Luke, David Nugraha, Dita Aulia Rachmi, Imanita Septianda, Maya Qurota A'yun
发表日期
2021/9/1
来源
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
卷号
15
期号
5
页码范围
102210
出版商
Elsevier
简介
Aims
This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes.
Methods
PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality.
Results
A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI: 0.98–1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI: 0.52–0.91], p = 0.009).
Conclusion
CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.
学术搜索中的文章
MY Alsagaff, EPB Mulia, I Maghfirah, K Luke… - Diabetes & Metabolic Syndrome: Clinical Research & …, 2021